Related Experiment Video
Updated: Jan 27, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
Comorbidity Index as a Predictor of Mortality in Pediatric Patients With Solid Tumors
Luz María Torres-Espíndola1, Joel Demetrio-Ríos1, Liliana Carmona-Aparicio2
1Pharmacology Laboratory, National Institute of Pediatrics, Mexico City, Mexico.
Insights
The Pediatric Comorbidity Index (PCI) effectively predicts mortality in children with solid tumors treated with chemotherapy. Higher comorbidity scores on the PCI correlate with lower survival rates, aiding clinical evaluation.
Area of Science:
- Pediatric Oncology
- Clinical Epidemiology
Background:
- Comorbidity indices are crucial for assessing patient prognosis.
- Predicting mortality in pediatric solid tumors requires validated tools.
Purpose of the Study:
- To evaluate the predictive value of comorbidity indices for mortality in pediatric patients with solid tumors receiving chemotherapy.
- To compare the prognostic performance of the Charlson Comorbidity Index (CCI) and the Pediatric Comorbidity Index (PCI).
Main Methods:
- Retrospective analysis of 196 pediatric patients with solid tumors treated with chemotherapy.
- Data collection included demographics, clinical information, and comorbidities from electronic health records.
- Kaplan-Meier curves were used to assess the prognostic value of CCI and PCI.
Main Results:
- Metastatic tumors were present in 52.6% of patients.
- Pneumonia and sepsis were the most frequent comorbidities in the PCI (32.7% each).
- Both CCI and PCI demonstrated significant prognostic value for mortality (p < 0.0001).
Conclusions:
- The PCI showed superior discrimination in predicting survival based on comorbidity burden compared to the CCI.
- Patients with no comorbidities had 100% survival, while those with high comorbidity had 20% survival using the PCI.
- The PCI is a valuable tool for clinical evaluation and prognosis assessment in hospitalized pediatric oncology patients.
Abstract:
Purpose: The objective of this study was to determine whether a comorbidity index could be used to predict mortality in pediatric patients with chemotherapy-treated solid tumors. Methods: Pediatric patients who underwent chemotherapy treatment for solid tumors were included, and demographic, clinical, and comorbidity data were obtained from patient electronic records. Results: A total of 196 pediatric patients with embryonic solid tumors were included. Metastatic tumors were the most frequently observed (n = 103, 52.6%). The most common comorbidities encountered for the Charlson comorbidity index (CCI) were cellulitis (n = 24, 12.2%) and acute renal failure (n = 15, 7.7%). For the Pediatric Comorbidity Index (PCI), the most frequent comorbidities were pneumonia and sepsis, with n = 64 (32.7%) for each. We evaluated established the prognostic values for both indexes using Kaplan-Meier curves, finding that the CCI and PCI could predict mortality with p < 0.0001. Conclusion: Using the PCI, we observed 100% survival in patients without comorbidities, 70% survival in patients with a low degree of comorbidity, and 20% survival in patients with a high degree of comorbidity. Greater discrimination of probability of survival could be achieved using degrees of comorbidity on the PCI than using degrees of comorbidity on the CCI. The application of the PCI for assessing the hospitalized pediatric population may be of importance for improving clinical evaluation.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids

